Important: This product is not authorized for administration until further notice by the FDA.
Labeler
Vaccine Procedure
Payment Allowance
Effective From
Effective To
Footnotes
My Fee
Regeneron
Injection, casirivimab and imdevimab, 2400 mg
$0.01
2020-11-21
2022-01-24
[1][9]
(your fee)
[1] Since we anticipate that providers, initially, will not incur a cost for the product, CMS will update the payment allowance at a later date. Providers should not bill for the product if they received it for free.
[9] On January 24, 2022, the FDA announced that, due to the high frequency of the Omicron variant, this product isn’t currently authorized in any U.S region and may not be administered for treatment or post-exposure prevention of COVID-19 under the EUA until further notice by the FDA.
Quick, Current, Complete - www.findacode.com